Hemodynamic responses and c-Fos changes associated with hypotensive hemorrhage: standardizing a protocol for severe hemorrhage in conscious rats.
The central mechanisms underlying the transition from compensation to decompensation during severe hemorrhage (HEM) are poorly understood. Furthermore, a lack of consistency in HEM protocols exists in the current literature. This study assessed the cardiovascular response and Fos-like immunoreactivity (FLI) in specific brain regions following severe HEM at three rates (2, 1, or 0.5 ml.kg(-1).min(-1)) in conscious rats. Heart rate (HR) and arterial pressure were recorded during the withdrawal of 30% of total blood volume (TBV). Data from animals hemorrhaged at the fast (F-HEM, n = 6), intermediate (I-HEM, n = 7), or slow (S-HEM, n = 7) rates were compared with saline (SAL, n = 5) and hypotensive (hydrazaline-induced, HYDRAZ, n = 5) controls. All HEM rates produced similar degrees of hypotension at the time of 30% TBV withdrawal. All HEM rates also produced bradycardia, but the change in HR was only significant in the F-HEM and I-HEM groups. Associated with I-HEM and F-HEM, but not HYDRAZ treatment were significant increases in FLI in the caudal ventrolateral periaqueductal gray (PAG), the central lateral nucleus of the rostral parabrachial nucleus, and locus coeruleus compared with SAL treatment. I-HEM also induced significant increases in FLI in the dorsomedial PAG, A7 region, and the cuneiform nucleus compared with SAL. S-HEM did not induce any significant change in FLI. Our results suggest that HEM at a rate of 1 ml.kg(-1).min(-1) may be most useful for investigating the potential role of the rostral brainstem regions in mediating hemorrhagic decompensation in conscious rats.
Ahlgren
Joslyn
J
Dept of Physiological Sciences, HSC, Univ of Florida, Gainesville, FL 32610, USA. jhanse3@hotmail.com
Porter
Karen
K
Hayward
Linda F
LF
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000378:metabolism; D003243:Consciousness; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006470:Hemorrhage / Q000150:complications* / Q000378:metabolism*; D006830:Hydralazine / Q000627:therapeutic use; D007022:Hypotension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D016760:Proto-Oncogene Proteins c-fos; D014665:Vasodilator Agents; D006830:Hydralazine; D012965:Sodium Chloride